KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Amortizatization of Intangibles (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 15 years of Amortizatization of Intangibles data on record, last reported at $670000.0 in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles fell 92.1% year-over-year to $670000.0; the TTM value through Dec 2025 reached $5.4 million, down 63.75%, while the annual FY2025 figure was $5.4 million, 63.75% down from the prior year.
  • Amortizatization of Intangibles reached $670000.0 in Q4 2025 per ACAD's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $8.5 million in Q4 2024 and bottomed at -$1.5 million in Q2 2021.
  • Average Amortizatization of Intangibles over 5 years is $1.8 million, with a median of $1.7 million recorded in 2023.
  • The widest YoY moves for Amortizatization of Intangibles: up 471.0% in 2021, down 486.5% in 2021.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $2.3 million in 2021, then tumbled by 80.43% to $447000.0 in 2022, then soared by 297.99% to $1.8 million in 2023, then surged by 376.45% to $8.5 million in 2024, then plummeted by 92.1% to $670000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $670000.0 in Q4 2025, $1.1 million in Q3 2025, and $1.5 million in Q2 2025.